$CHRS
Coherus BioSciences Inc

2019 Q3 Form 10-Q Financial Statement

#000156459019042255 Filed on November 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q3
Revenue $111.7M $83.43M $0.00
YoY Change
Cost Of Revenue $6.400M $601.0K
YoY Change
Gross Profit $105.2M $82.83M
YoY Change
Gross Profit Margin 94.23% 99.28%
Selling, General & Admin $31.83M $36.46M $25.37M
YoY Change 25.46% 98.23% 81.21%
% of Gross Profit 30.24% 44.01%
Research & Development $21.57M $18.88M $31.60M
YoY Change -31.75% -28.79% -25.86%
% of Gross Profit 20.49% 22.8%
Depreciation & Amortization $800.0K $700.0K $800.0K
YoY Change 0.0% -22.22% 0.0%
% of Gross Profit 0.76% 0.85%
Operating Expenses $59.84M $55.94M $56.97M
YoY Change 5.04% 24.56% 0.63%
Operating Profit $51.84M $27.49M
YoY Change -161.22%
Interest Expense $4.469M $4.433M $2.425M
YoY Change 84.29% -284.71% 1.38%
% of Operating Profit 8.62% 16.12%
Other Income/Expense, Net $518.0K $558.0K $571.0K
YoY Change -9.28% -84.5% 3978.57%
Pretax Income $47.89M $23.62M -$58.83M
YoY Change -181.41% -154.06% -0.29%
Income Tax $800.0K $51.00K $0.00
% Of Pretax Income 1.67% 0.22%
Net Earnings $47.04M $23.57M -$58.81M
YoY Change -179.99% -154.01% -0.31%
Net Earnings / Revenue 42.12% 28.25%
Basic Earnings Per Share $0.67 $0.34
Diluted Earnings Per Share $0.63 $0.32 -$867.3K
COMMON SHARES
Basic Shares Outstanding 69.88M 69.48M
Diluted Shares Outstanding 78.53M 72.96M 67.85M

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $170.5M $111.9M $117.2M
YoY Change 45.48% -29.97% -21.92%
Cash & Equivalents $165.1M $105.9M $101.2M
Short-Term Investments $5.400M $6.000M $16.00M
Other Short-Term Assets $8.600M $12.00M $13.10M
YoY Change -34.35% -7.69% -39.35%
Inventory $7.668M $4.333M
Prepaid Expenses
Receivables $89.60M $77.40M
Other Receivables $0.00 $0.00
Total Short-Term Assets $276.4M $205.6M $130.3M
YoY Change 112.11% 19.0% -24.07%
LONG-TERM ASSETS
Property, Plant & Equipment $5.857M $5.646M $6.800M
YoY Change -13.87% -49.59% -50.72%
Goodwill $943.0K $943.0K
YoY Change
Intangibles $2.620M $2.620M
YoY Change
Long-Term Investments
YoY Change
Other Assets $514.0K $14.00K $800.0K
YoY Change -35.75% -98.25% 0.0%
Total Long-Term Assets $51.01M $34.83M $11.20M
YoY Change 355.43% 124.68% -38.46%
TOTAL ASSETS
Total Short-Term Assets $276.4M $205.6M $130.3M
Total Long-Term Assets $51.01M $34.83M $11.20M
Total Assets $327.4M $240.5M $141.5M
YoY Change 131.37% 27.7% -25.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.71M $19.22M $7.600M
YoY Change 80.38% 44.53% -24.75%
Accrued Expenses $16.47M $8.295M $16.50M
YoY Change -0.16% -2.41% -1.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $82.70M $61.23M $24.50M
YoY Change 237.56% 175.82% -21.97%
LONG-TERM LIABILITIES
Long-Term Debt $177.8M $177.2M $102.7M
YoY Change 73.13% 73.22% 1.38%
Other Long-Term Liabilities $0.00 $0.00 $1.800M
YoY Change -100.0% -100.0% -18.18%
Total Long-Term Liabilities $0.00 $0.00 $104.5M
YoY Change -100.0% -100.0% 0.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $82.70M $61.23M $24.50M
Total Long-Term Liabilities $0.00 $0.00 $104.5M
Total Liabilities $271.4M $244.4M $129.1M
YoY Change 110.19% 93.26% -3.37%
SHAREHOLDERS EQUITY
Retained Earnings -$981.3M
YoY Change
Common Stock $977.8M
YoY Change 5.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.00M -$4.000M $12.40M
YoY Change
Total Liabilities & Shareholders Equity $327.4M $240.5M $141.5M
YoY Change 131.38% 27.7% -25.43%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q3
OPERATING ACTIVITIES
Net Income $47.04M $23.57M -$58.81M
YoY Change -179.99% -154.01% -0.31%
Depreciation, Depletion And Amortization $800.0K $700.0K $800.0K
YoY Change 0.0% -22.22% 0.0%
Cash From Operating Activities $54.90M $12.70M -$42.80M
YoY Change -228.27% -135.77% 3.13%
INVESTING ACTIVITIES
Capital Expenditures -$900.0K -$200.0K -$500.0K
YoY Change 80.0% -72.22%
Acquisitions
YoY Change
Other Investing Activities $700.0K $9.000M $13.30M
YoY Change -94.74% -154.22% -56.54%
Cash From Investing Activities -$300.0K $8.800M $12.80M
YoY Change -102.34% -153.01% -55.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.700M 3.000M 1.000M
YoY Change 270.0% -97.0% -98.67%
NET CHANGE
Cash From Operating Activities 54.90M 12.70M -42.80M
Cash From Investing Activities -300.0K 8.800M 12.80M
Cash From Financing Activities 3.700M 3.000M 1.000M
Net Change In Cash 58.30M 24.50M -29.00M
YoY Change -301.03% -48.74% -146.55%
FREE CASH FLOW
Cash From Operating Activities $54.90M $12.70M -$42.80M
Capital Expenditures -$900.0K -$200.0K -$500.0K
Free Cash Flow $55.80M $12.90M -$42.30M
YoY Change -231.91% -136.34% 6.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001512762
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
649-3530
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CHRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165116000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72356000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5377000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2019Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
89646000
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
0
CY2019Q3 us-gaap Inventory Net
InventoryNet
7668000
CY2018Q4 us-gaap Inventory Net
InventoryNet
1659000
CY2019Q3 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
5381000
CY2018Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
7906000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3137000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2462000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
276375000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
84433000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5857000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6660000
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
232215000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60337000
CY2019Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
29941000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
4012000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11133000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2620000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2620000
CY2019Q3 us-gaap Goodwill
Goodwill
943000
CY2018Q4 us-gaap Goodwill
Goodwill
943000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
785000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
514000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14000
CY2019Q3 us-gaap Assets
Assets
327383000
CY2018Q4 us-gaap Assets
Assets
99467000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13709000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15294000
CY2019Q3 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
37121000
CY2018Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
0
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13352000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10540000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16474000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7008000
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2045000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
419000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
82701000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33261000
CY2019Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
59000
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
60000
CY2019Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
78226000
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
77319000
CY2019Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
26075000
CY2018Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25773000
CY2019Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
73472000
CY2018Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
0
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10827000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1645000
CY2019Q3 us-gaap Liabilities
Liabilities
271360000
CY2018Q4 us-gaap Liabilities
Liabilities
138058000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
111684000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2019Q3 chrs Cost Of Sold Goods
CostOfSoldGoods
6447000
CY2018Q3 chrs Cost Of Sold Goods
CostOfSoldGoods
0
chrs Cost Of Sold Goods
CostOfSoldGoods
9273000
chrs Cost Of Sold Goods
CostOfSoldGoods
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83577000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31828000
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25369000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
56972000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
51841000
us-gaap Interest Expense
InterestExpense
7250000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
100967000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1887000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4351000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
47890000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58826000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
51504000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-146813000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
847000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
898000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Profit Loss
ProfitLoss
47043000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-58826000
us-gaap Profit Loss
ProfitLoss
50606000
us-gaap Profit Loss
ProfitLoss
-146813000
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2018Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-18000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
47043000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-58808000
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.39
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69501835
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61414876
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67848730
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72872076
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61414876
CY2019Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
CY2018Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
1000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
100000
CY2019Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
615000
CY2018Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
606000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1839000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1812000
CY2019Q1 chrs Other Comprehensive Income Loss Cumulative Translation Adjustment
OtherComprehensiveIncomeLossCumulativeTranslationAdjustment
-136000
CY2019Q2 chrs Other Comprehensive Income Loss Cumulative Translation Adjustment
OtherComprehensiveIncomeLossCumulativeTranslationAdjustment
-93000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
23567000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3985000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3707000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9199000
CY2019Q3 chrs Other Comprehensive Income Loss Cumulative Translation Adjustment
OtherComprehensiveIncomeLossCumulativeTranslationAdjustment
59000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
30535000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
225000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2018Q1 chrs Other Comprehensive Income Loss Cumulative Translation Adjustment
OtherComprehensiveIncomeLossCumulativeTranslationAdjustment
-13000
CY2018Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
5000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-44297000
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3088000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
284000
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
764000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8690000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2018Q2 chrs Other Comprehensive Income Loss Cumulative Translation Adjustment
OtherComprehensiveIncomeLossCumulativeTranslationAdjustment
226000
CY2018Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
47000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-43638000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61831000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1399000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8559000
CY2018Q3 chrs Other Comprehensive Income Loss Cumulative Translation Adjustment
OtherComprehensiveIncomeLossCumulativeTranslationAdjustment
117000
CY2018Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
18000
CY2018Q3 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-700000
CY2018Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12394000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2204000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2622000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3220000
chrs Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
0
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
89646000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
31151000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2525000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5193000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
653000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-348000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
500000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
5828000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1436000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-7757000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
0
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-233000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
37121000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
0
us-gaap Share Based Compensation
ShareBasedCompensation
26319000
us-gaap Share Based Compensation
ShareBasedCompensation
25970000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
142000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
269000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1726000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1100000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-3862000
chrs Excess And Obsolete Inventory
ExcessAndObsoleteInventory
410000
chrs Excess And Obsolete Inventory
ExcessAndObsoleteInventory
0
chrs Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1305000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
4162000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9416000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1786000
chrs Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1590000
chrs Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-30000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-320000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10645000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111903000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1435000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
575000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20235000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42869000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27170000
chrs Payments To Acquire Interest In Related Party
PaymentsToAcquireInterestInRelatedParty
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6670000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16974000
chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts
8153000
chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts
100286000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
72955000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5184000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1778000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1878000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
764000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88170000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
102828000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-170000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
91975000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25719000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73191000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127756000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165166000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102037000
chrs Non Cash Bonus Payment Settled In Common Stock
NonCashBonusPaymentSettledInCommonStock
1350000
chrs Non Cash Bonus Payment Settled In Common Stock
NonCashBonusPaymentSettledInCommonStock
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5267000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
chrs Non Cash Minority Interest Reflected In Additional Paid In Capital
NonCashMinorityInterestReflectedInAdditionalPaidInCapital
0
chrs Non Cash Minority Interest Reflected In Additional Paid In Capital
NonCashMinorityInterestReflectedInAdditionalPaidInCapital
1359000
us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization and Operations<font style="font-weight:normal;"> </font></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coherus BioSciences, Inc. (the &#8220;Company&#8221;, &#8220;Coherus&#8221;, &#8220;we&#8221;, our&#8221; or &#8220;us&#8221;) is a commercial-stage biotherapeutics company, focused on the global biosimilar market. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2018, the Company received regulatory approval for the marketing of UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, from the European Commission, and received regulatory approval for UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on November 2, 2018. The Company initiated U.S. sales of UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> on January 3, 2019.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital<font style="font-weight:normal;"> </font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019, the Company had an accumulated deficit of $934.2 million and cash, cash equivalents and short-term investments in marketable securities of $170.5 million. In January 2019, the Company issued and sold 761,130 shares of common stock at a weighted average price of $11.17 per share through its ATM Offering Program and received total net proceeds of $8.2 million (see Note 10). As of January 19, 2019, the Company&#8217;s Shelf Registration Statement expired and accordingly the ATM Program was terminated. <font style="color:#000000;">The Company also entered into a credit agreement (the &#8220;Term Loan&#8221;) with affiliates of Healthcare Royalty Partners consisting of a six-year term loan facility for an aggregate principal of $75.0 million in January 2019.</font> The Company believes that its current available cash, cash equivalents, short-term investments in marketable securities and cash collected from <font style="color:#000000;">UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> sales </font>will be sufficient to fund its planned expenditures and meet the Company&#8217;s obligations <font style="color:#000000;">for at least 12 months following our financial statement issuance date</font><font style="color:#1F497D;">. </font>Although the Company was profitable for the three and nine months ended September 30, 2019, the Company may need to raise additional funds in the future; however, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to generate sufficient cash from product sales or to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.&nbsp;&nbsp;</p>
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3171000
CY2019Q3 chrs Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
2614000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15802000
CY2019Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
170500000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-409000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101202000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
785000
chrs Write Off Of Prepaid Manufacturing Costs
WriteOffOfPrepaidManufacturingCosts
1300000
us-gaap Inventory Write Down
InventoryWriteDown
400000
us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
0
CY2019Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.00
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7200000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9200000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2018 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
36000
CY2018Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
233000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
293000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
459000
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2018Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2019Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4722000
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2851000
CY2019Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
30024000
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1576000
CY2019Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2863000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1244000
CY2019Q3 us-gaap Inventory Gross
InventoryGross
37609000
CY2018Q4 us-gaap Inventory Gross
InventoryGross
5671000
CY2019Q3 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
37609000
CY2018Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5671000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21098000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19697000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15241000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13037000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2018Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2019Q3 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
6770000
CY2018Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
3950000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9704000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3058000
CY2018Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
0
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
206006000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
137911000
CY2019Q3 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
68095000
CY2019Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
133600000
CY2019Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
6947000
CY2019Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
29350000
CY2019Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
14753000
CY2019Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
8403000
CY2019Q3 us-gaap Purchase Obligation
PurchaseObligation
59453000
CY2015Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
40341
chrs Number Of Laboratory Facility Structure
NumberOfLaboratoryFacilityStructure
2
CY2019Q3 chrs Additional Area Of Real Estate Property Leased
AdditionalAreaOfRealEstatePropertyLeased
7448
CY2019Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
47789
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2045000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12872000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
600000
us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
700000
us-gaap Operating Lease Payments
OperatingLeasePayments
2000000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
669000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3141000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3173000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3034000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2930000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69877693
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67848730
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69501835
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61414876
CY2019Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2462000
CY2018Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0
CY2019Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
49505000
CY2018Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-58808000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
50606000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-146743000
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4165666
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3353962
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2019Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
12997
CY2018Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
16279
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0
CY2019Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4473871
CY2018Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2019Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
78530227
CY2018Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
67848730
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
72872076
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
61414876
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6475843
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18618894
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14761863
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18618894

Files In Submission

Name View Source Status
0001564590-19-042255-index-headers.html Edgar Link pending
0001564590-19-042255-index.html Edgar Link pending
0001564590-19-042255.txt Edgar Link pending
0001564590-19-042255-xbrl.zip Edgar Link pending
chrs-10q_20190930.htm Edgar Link pending
chrs-20190930.xml Edgar Link completed
chrs-20190930.xsd Edgar Link pending
chrs-20190930_cal.xml Edgar Link unprocessable
chrs-20190930_def.xml Edgar Link unprocessable
chrs-20190930_lab.xml Edgar Link unprocessable
chrs-20190930_pre.xml Edgar Link unprocessable
chrs-ex101_9.htm Edgar Link pending
chrs-ex102_233.htm Edgar Link pending
chrs-ex311_6.htm Edgar Link pending
chrs-ex312_7.htm Edgar Link pending
chrs-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending